Needham & Company LLC reiterated their buy rating on shares of Privia Health Group (NASDAQ:PRVA - Free Report) in a report issued on Thursday,Benzinga reports. They currently have a $30.00 price target on the stock.
A number of other brokerages also recently weighed in on PRVA. Macquarie assumed coverage on shares of Privia Health Group in a research note on Monday, December 16th. They set an "outperform" rating and a $25.00 target price for the company. JMP Securities set a $29.00 target price on shares of Privia Health Group in a research report on Friday, February 28th. Canaccord Genuity Group boosted their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $26.00 target price on shares of Privia Health Group in a research note on Thursday, January 2nd. Finally, Truist Financial lifted their price target on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $27.00.
View Our Latest Report on PRVA
Privia Health Group Stock Performance
Shares of Privia Health Group stock traded down $0.01 during trading on Thursday, reaching $24.04. 130,278 shares of the company's stock were exchanged, compared to its average volume of 784,615. The firm's 50-day moving average price is $23.77 and its 200 day moving average price is $21.56. The company has a market cap of $2.92 billion, a P/E ratio of 240.42, a PEG ratio of 3.47 and a beta of 0.88. Privia Health Group has a 1-year low of $15.92 and a 1-year high of $26.04.
Insider Buying and Selling at Privia Health Group
In other news, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares in the company, valued at approximately $4,021,148.88. The trade was a 3.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.20% of the stock is owned by corporate insiders.
Institutional Trading of Privia Health Group
Hedge funds have recently bought and sold shares of the stock. Riverbridge Partners LLC lifted its stake in shares of Privia Health Group by 19.7% during the 4th quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company's stock worth $113,868,000 after purchasing an additional 958,418 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Privia Health Group by 55.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,418,234 shares of the company's stock valued at $27,727,000 after buying an additional 503,002 shares in the last quarter. Durable Capital Partners LP grew its position in shares of Privia Health Group by 3.4% in the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company's stock worth $224,587,000 after buying an additional 378,255 shares during the last quarter. BlackBarn Capital Partners LP grew its position in shares of Privia Health Group by 65.8% in the 4th quarter. BlackBarn Capital Partners LP now owns 663,397 shares of the company's stock worth $12,969,000 after buying an additional 263,397 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Privia Health Group by 19.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company's stock valued at $29,110,000 after acquiring an additional 246,393 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.
About Privia Health Group
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
See Also
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
